Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles

@inproceedings{Davis2010EvidenceOR,
  title={Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles},
  author={Mark E Davis and Jonathan E. Zuckerman and Chung Hang Jonathan Choi and David B. Seligson and Anthony William Tolcher and Christopher A Alabi and Yun Yen and Jeremy David Heidel and Antoni Ribas},
  booktitle={Nature},
  year={2010}
}
Therapeutics that are designed to engage RNA interference (RNAi) pathways have the potential to provide new, major ways of imparting therapy to patients. Long, double-stranded RNAs were first shown to mediate RNAi in Caenorhabditis elegans, and the potential use of RNAi for human therapy has been demonstrated by the finding that small interfering RNAs (siRNAs; approximately 21-base-pair double-stranded RNA) can elicit RNAi in mammalian cells without producing an interferon response. We are at… CONTINUE READING
Highly Influential
This paper has highly influenced 17 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 724 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

from concept to clinic

  • Davis, M. E. The first targeted delivery of siRNA in humans self-assembling, cyclodextrin polymer-based nanoparticle
  • Mol. Pharm. 6, 659–668
  • 2009

Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV)

  • J DeVincenzo
  • Antiviral Res
  • 2008

Similar Papers

Loading similar papers…